This is a huge issue. In general, the homogeneity of the clinical trial is a concern for getting generalizable effect sizes. This is why there is a movement toward the pragmatic clinical trial.
Boo hoo it just shows that we don't care about race as much anymore.
Guess it doesn't help when the journal name is Scientific America.
Without reading the article yet, wouldn't access to those certain populations matter?